关键词：抗凝剂；防御；凝血障碍；深静脉血栓形成；PE；急性冠状动脉综合征；传统疗法；口服抗凝血剂；安全性；有效性
摘 要：Anticoagulants are the first line of defense for clotting disorders such as DVT, PE, AF, and acute coronary syndrome. Traditional therapies have now been replaced by novel oral anticoagulants, which have better safety and efficacy profiles.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Anticoagulants: An overview

Coagulation of blood

Mechanism of action (MOA) of anticoagulants

PART 06: Reimbursement scenario

US healthcare reform

Reimbursement for prothrombin time/international

normalized ratio (PT/INR) tests

PART 07: Anticoagulant reversal agents

PART 08: Approved anticoagulants in US

PART 09: Anticoagulants pipeline portfolio

Rivaroxaban

Tecarfarin

Betrixaban (LY517717)

ISIS-FXI antisense

LMW Heparin MMX

URG101

Heparin

FXI antibody

FXI inhibitor

Heparin plus DNAse

Heparin plus other inhaled drug

PART 10: Market landscape

Global anticoagulants market

Anticoagulants market in US

Five forces analysis

PART 11: Market segmentation by ROA

Oral anticoagulants

Injectable anticoagulants

PART 12: Market segmentation by drug class

Factor Xa inhibitors

Direct thrombin inhibitors

Heparin

Vitamin K antagonists

PART 13: Market segmentation by application

DVT

PE

Acute coronary syndrome

AF

Hemodialysis

Coronary angioplasty

Surgeries

PART 14: Market drivers

Growing prevalence of coagulation disorders

Increase in number of surgical procedures

Increased acceptance of NOACs

PART 15: Impact of drivers

PART 16: Market challenges

Extensive use of generic products

Side-effects associated with drugs

High cost of NOACs

Unmet needs for anticoagulant reversal agents

PART 17: Impact of drivers and challenges

PART 18: Market trends

Expected exploitation of new therapeutic use

Patient assistance programs

Declining shares of heparin market

PART 19: Vendor landscape

Competitive scenario

Market analysis 2015

Key vendors of anticoagulants market in US

Johnson & Johnson

Bristol-Myers Squibb

Boehringer Ingelheim

Sanofi

Upcoming vendors in anticoagulants market in US

Daiichi Sankyo

Other prominent vendors

PART 20: Appendix

List of abbreviations

PART 21: Explore Technavio